Prostate cancer: Can imaging substitute for repeat biopsies during active surveillance? - Harvard Health Harvard Health Publishing Harvard Health Publishing Open mobile menu Menu Close menu Close

Recent Blog Articles

Healthy oils at home and when eating out Why life expectancy in the US is falling Breakthrough in brain stimulation offers cautious hope for depression How well do colonoscopies prevent colorectal cancer? What you need to know How can you find joy (or at least peace) during difficult times? The mental health crisis among children and teens: How parents can help The latest thinking on dry eye treatments What’s the relationship between memory loss and driving? Inflammatory bowel disease: Issues outside the gut Prostate cancer Can imaging substitute for repeat biopsies during active surveillance / Men's Health

Prostate cancer Can imaging substitute for repeat biopsies during active surveillance

October 7, 2022 By Charlie Schmidt, Editor, Harvard Medical School Annual Report on Prostate Diseases

A new study says yes but not without limited risks

If you've been diagnosed with low- or intermediate-risk prostate cancer, the good news is that you don't have to treat it right away. Since the cancer will likely grow slowly (if at all), you can have the cancer monitored and treated only if it shows signs of progression. This is called active surveillance. More men are choosing active surveillance, which entails repeat prostate-specific antigen (PSA) tests and prostate biopsies to check for tumor growth. This way you can delay - and maybe even avoid - cancer treatment and its side effects. But repeat biopsies can also be painful and stressful, and they come with a small risk of infection. A newer type of imaging provides an alternative. Called multiparametric magnetic resonance imaging (mpMRI), it allows doctors to visualize prostate cancer from outside of the body. This type of scanning has become more widely adopted for active surveillance, and "may help to reduce the frequency of subsequent repeat biopsy, particularly among men with stable PSA," says Dr. Boris Gershman, a urologic surgeon at Beth Israel Deaconess Medical Center in Boston, and a member of the Harvard Medical School Annual Report on Prostate Diseases advisory board.

Studying mpMRI' s effectiveness

One outstanding question is if mpMRI can substitute for a "confirmatory biopsy" that men typically get a year or so into the monitoring process to see if the cancer is still stable. The risk is that an mpMRI could miss worsening cancer that a confirmatory biopsy would otherwise detect. To investigate, a team of Australian researchers performed a newly published study. They enrolled 172 men with low- or intermediate-risk prostate cancer, and gave them an mpMRI followed by a prostate biopsy. After that, the men were followed on an active surveillance protocol for three years. They got PSA checks every six months, yearly digital rectal exams, and an mpMRI scan at the end of years one and two. If the PSA and/or mpMRI findings suggested worsening cancer, then the men had a biopsy. If not, biopsies were delayed until the study wrapped up three years later. Upon analyzing the results, the team found that mpMRI scans were better at ruling out cancer progression than at detecting it. Specifically, the odds that an mpMRI scan would detect clinically significant cancer (the kind that needs more immediate treatment) that a biopsy would later confirm ranged from 50% to 57%. By contrast, the odds that a scan would correctly show the absence of worsening cancer ranged between 82% and 86%.

Conclusions and caveats

Based on these results, the investigators concluded that men with negative mpMRI scans can safely omit the one-year confirmatory biopsy. However, men should still get a standard three-year biopsy, they wrote, "due to occasional MRI-invisible tumors." The team plans to follow the men and present 10-year data at some point in the future. Other experts take a more cautious view. Dr. Gershman, for instance, expressed concern about mpMRI's limited capacity to detect clinically significant cancer during active surveillance. But he added that despite its limitations, the scanning technology is still a useful tool "that should allow increased time between repeat biopsies in men at otherwise low risk of progression." "This study adds to better understanding the utility of mpMRI in the continued evaluation of men on active surveillance," says Dr. Marc B. Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center. "The upside of the study is that more biopsies can potentially be avoided. The downside is for patients to understand that the MRI is not an equal substitute for biopsy: a negative MRI finding may have missed a clinically significant cancer. In my own practice, I have used MRI to monitor men, along with digital rectal examinations and PSA evaluations on active surveillance instead of repeated biopsies, but only with the patient's full understanding that a small number of potential clinically significant cancers may not be detected by this practice."

About the Author

Charlie Schmidt, Editor, Harvard Medical School Annual Report on Prostate Diseases Charlie Schmidt is an award-winning freelance science writer based in Portland, Maine. In addition to writing for Harvard Health Publishing, Charlie has written for Science magazine, the Journal of the National Cancer Institute, Environmental Health Perspectives, … See Full Bio View all posts by Charlie Schmidt Share This Page Share this page to Facebook Share this page to Twitter Share this page via Email Print This Page Click to Print

Disclaimer

As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician. You might also be interested in…

2022 Annual Report on Prostate Diseases

Most men eventually develop some type of prostate problem, and when they do there are usually no easy solutions. More than a primer on prostate conditions, this Special Health Report, the Annual Report on Prostate Diseases, includes roundtable discussions with experts at the forefront of prostate research, interviews with men about their treatment decisions, and the latest thinking on complementary therapies. This report will provide you with the information you need to understand the current controversies, avoid common pitfalls, and work with your doctor to make informed choices about your prostate health. Read More

Related Content

Men's Health

Leaking a little urine It s not just a female problem

Men's Health

What s the best way to test for low testosterone

Men's Health

Prostate cancer Radiation therapy elevates risk for future cancers

Prostate Health Prostate Cancer Prostate Knowledge

Free Healthbeat Signup

Get the latest in health news delivered to your inbox! Sign Up Close Thanks for visiting. Don't miss your FREE gift. The Best Diets for Cognitive Fitness, is yours absolutely FREE when you sign up to receive Health Alerts from Harvard Medical School Sign up to get tips for living a healthy lifestyle, with ways to fight inflammation and improve cognitive health, plus the latest advances in preventative medicine, diet and exercise, pain relief, blood pressure and cholesterol management, and more. I want to get healthier Close Health Alerts from Harvard Medical School Get helpful tips and guidance for everything from fighting inflammation to finding the best diets for weight loss...from exercises to build a stronger core to advice on treating cataracts. PLUS, the latest news on medical advances and breakthroughs from Harvard Medical School experts. BONUS! Sign up now and
get a FREE copy of the
Best Diets for Cognitive Fitness I want to get healthier Close Stay on top of latest health news from Harvard Medical School. Plus, get a FREE copy of the Best Diets for Cognitive Fitness. Sign me up